Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Brii Biosciences Limited
  6. Summary
    2137   KYG1645A1094

BRII BIOSCIENCES LIMITED

(2137)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
47.85 44.75 39.8 40.8 42.7 Last
2674907 4059020 2271214 2845238 2139500 Volume
+9.12% -6.48% -11.06% +2.51% +4.66% Change
Estimated financial data (e)
Sales 2021 350 M 54,9 M 54,9 M
Net income 2021 -2 030 M -318 M -318 M
Net cash position 2021 3 857 M 605 M 605 M
P/E ratio 2021 -8,41x
Yield 2021 -
Sales 2022 3 798 M 596 M 596 M
Net income 2022 3 404 M 534 M 534 M
Net cash position 2022 3 011 M 472 M 472 M
P/E ratio 2022 9,90x
Yield 2022 -
Capitalization 25 157 M 3 945 M 3 946 M
EV / Sales 2021 60,8x
EV / Sales 2022 5,83x
Nbr of Employees 98
Free-Float 89,3%
More Financials
Company
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The CompanyÔÇÖs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous... 
More about the company
All news about BRII BIOSCIENCES LIMITED
11/21Evergrande to Be Booted From HSI’s China Enterprises Index
MT
11/19Brii Biosciences Joins Hang Seng Composite Index
PR
11/17Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021..
PR
11/16China Nears Approval of First COVID-19 Drug
MT
11/16China hopes to approve first Covid-19 drug in December
AQ
10/11BRII BIOSCIENCES : Seeks Emergency Use Authorization in US for COVID-19 Combination Therap..
MT
10/10Brii Biosciences Limited Files Emergency Use Authorization Application for the Investig..
CI
10/08BRII BIOSCIENCES : Bio Initiates Submission of Emergency Use Authorization Filing to U.S. ..
PR
09/28Brii Biosciences Limited Appoints Coy Stout as Senior Vice President and Head of U.S. M..
CI
09/27BRII BIOSCIENCES : Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market..
PR
09/08BRII BIOSCIENCES : Making $100 Million Further Investment in Combination Therapy for COVID..
MT
09/07BRII BIOSCIENCES : Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combi..
PR
09/07Brii Biosciences Adds USD 100 Million to Advance its Late-Stage Monoclonal Antibody Com..
CI
08/26Brii Biosciences Limited Announces Unaudited Consolidated Earnings Results for the Six ..
CI
08/24BRII BIOSCIENCES : Says Combination Therapy for COVID-19 Trims Hospitalization, Death; Sha..
MT
More news
News in other languages on BRII BIOSCIENCES LIMITED
11/21Evergrande va être exclu de l'indice HSI des entreprises chinoises
10/11Brii Biosciences demande une autorisation d'utilisation d'urgence aux États-Unis pour l..
08/06Brii Bio lève 38 millions de dollars grâce à l'exercice partiel de l'option de suralloc..
07/13Les actions de Hong Kong affichent une série de gains sur trois jours ; Brii Bio augmen..
More news
Chart BRII BIOSCIENCES LIMITED
Duration : Period :
Brii Biosciences Limited Technical Analysis Chart | 2137 | KYG1645A1094 | MarketScreener
Technical analysis trends BRII BIOSCIENCES LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 34,93 CNY
Average target price 38,08 CNY
Spread / Average Target 9,03%
EPS Revisions
Managers and Directors
Zhi Hong Chairman & Chief Executive Officer
Yong Qing Luo President & Executive Director
An Kang Li Chief Financial Officer & Joint Secretary
Martin J. Murphy Independent Non-Executive Director
Hui Tang Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
BRII BIOSCIENCES LIMITED0.00%3 945
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819